Effective Drug Delivery, In Vitro and In Vivo, by Carbon-Based Nanovectors Noncovalently Loaded with Unmodified Paclitaxel
Source abstract
Abstract
Many new drugs have low aqueous solubility and high therapeutic efficacy. Paclitaxel (PTX) is a classic example of this type of compound. Here we show that extremely small (<40 nm) hydrophilic carbon clusters (HCCs) that are PEGylated (PEG-HCCs) are effective drug delivery vehicles when simply mixed with paclitaxel. This formulation of PTX sequestered in PEG-HCCs (PTX/PEG-HCCs) is stable for at least 20 weeks. The PTX/PEG-HCCs formulation was as effective as PTX in a clinical formulation in reducing tumor volumes in an orthotopic murine model of oral squamous cell carcinoma. Preliminary toxicity and biodistribution studies suggest that the PEG-HCCs are not acutely toxic and, like many other nanomaterials, are primarily accumulated in the liver and spleen. This work demonstrates that carbon nanomaterials are effective drug delivery vehicles in vivo when noncovalently loaded with an unmodified drug.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Carbon and Quantum Dots Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry
Head and Neck Surgery, Unit 441
Thoracic/Head and Neck Medical Oncology
Experimental Diagnostic Imaging
Department of Veterinary Medicine and Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030
Smalley Institute for Nanoscale Science and Technology, Rice University, MS-222, 6100 Main Street, Houston, Texas 77005
References (48)
Show source-provided references
1. O’Driscoll C. M. · Adv. Drug Delivery Rev. · 2008 · 60 · 61710.1016/j.addr.2007.10.012 ↗
2. Stinchcombe T. E. · Nanomedicine · 2007 · 2 · 41510.2217/17435889.2.4.415 ↗
3. Gradishar W. J. · J. Clin. Oncol. · 2005 · 23 · 779410.1200/JCO.2005.04.937 ↗
4. Gursoy N. · J. Pharm. Sci. · 2003 · 92 · 241110.1002/jps.10501 ↗
5. Chen H. · Pharm. Res. · 2003 · 20 · 130210.1023/A:1025021603288 ↗
6. Crosasso P. · J. Controlled Release · 2000 · 63 · 1910.1016/S0168-3659(99)00166-2 ↗
7. Shuai X. T. · Bioconjugate Chem. · 2004 · 15 · 44110.1021/bc034113u ↗
8. Ruan G. · Biomaterials · 2003 · 24 · 503710.1016/S0142-9612(03)00419-8 ↗
9. Riehemann K. · Angew. Chem., Int. Ed. · 2009 · 48 · 87210.1002/anie.200802585 ↗
10. Ferrari M. · Nat. Rev. Cancer · 2005 · 5 · 16110.1038/nrc1566 ↗
11. Lee C. C. · Nat. Biotechnol. · 2005 · 23 · 151710.1038/nbt1171 ↗
12. Kostarelos K. · Nat. Nanotechnol. · 2009 · 4 · 62710.1038/nnano.2009.241 ↗
13. Wu H.-C. · J. Mater. Chem. · 2010 · 20 · 103610.1039/B911099M ↗
14. Yinghuai A. · J. Am. Chem. Soc. · 2005 · 127 · 987510.1021/ja0517116 ↗
15. Bhirde A. A. · ACS Nano · 2009 · 3 · 30710.1021/nn800551s ↗
16. Chen J. · J. Am. Chem. Soc. · 2008 · 130 · 1677810.1021/ja805570f ↗
17. Liu Z. · Cancer Res. · 2008 · 68 · 665210.1158/0008-5472.CAN-08-1468 ↗
18. Jesorka A. · Annu. Rev. Anal. Chem. · 2008 · 1 · 80110.1146/annurev.anchem.1.031207.112747 ↗
19. Harrington K. J. · Ann. Oncol. · 2001 · 12 · 49310.1023/A:1011199028318 ↗
20. Zhang X. · Biomaterials · 2009 · 30 · 604110.1016/j.biomaterials.2009.07.025 ↗
21. Heister E. · Carbon · 2009 · 47 · 215210.1016/j.carbon.2009.03.057 ↗
22. Sun X. · Nano Res. · 2008 · 1 · 20310.1007/s12274-008-8021-8 ↗
23. Liu Z. · J. Am. Chem. Soc. · 2008 · 130 · 1087610.1021/ja803688x ↗
24. Ali-Boucetta H. · Chem. Commun. · 2008 · 45910.1039/B712350G ↗
25. Liu Z. · ACS Nano · 2007 · 1 · 5010.1021/nn700040t ↗
26. Partha R. · ACS Nano · 2008 · 2 · 195010.1021/nn800422k ↗
27. Lay C. L. · Nanotechnology · 2010 · 21 · 06510110.1088/0957-4484/21/6/065101 ↗
28. Guo L. · Mater. Sci. Forum · 2007 · 544 · 51110.4028/www.scientific.net/MSF.544-545.511 ↗
29. Drezek R. A. · Nat. Nanotechnol. · 2010 · 5 · 16810.1038/nnano.2010.37 ↗
30. Hurt R. · Carbon · 2006 · 44 · 102810.1016/j.carbon.2005.12.023 ↗
31. Liu Z. · Proc. Natl. Acad. Sci. U.S.A. · 2008 · 105 · 141010.1073/pnas.0707654105 ↗
32. Schipper M. L. · Nat. Nanotechnol. · 2008 · 3 · 21610.1038/nnano.2008.68 ↗
33. Kolosnjaj-Tabi J. · ACS Nano · 2010 · 4 · 148110.1021/nn901573w ↗
34. Liu X. · Carbon · 2010 · 48 · 196110.1016/j.carbon.2010.02.002 ↗
35. Chen Z. · J. Am. Chem. Soc. · 2006 · 128 · 1056810.1021/ja063283p ↗
36. Price B. K. · Chem. Mater. · 2009 · 21 · 391710.1021/cm9021613 ↗
37. Duque J. G. · ACS Nano · 2010 · 4 · 306310.1021/nn100170f ↗
38. Stephenson J. J. · Chem. Mater. · 2007 · 19 · 349110.1021/cm070076v ↗
39. Recently, we have developed a different preparation that makes use of increased equivalents of PEG and DCC to synthesize the PEG-HCCs that allows up to 12 mg/mL of PTX to be sequestered. This improved synthesis was developed after the initiation of thein vitroandin vivoexperiments described, so the higher-loaded nanovectors were not used.
40. Myers J. N. · Clin. Cancer Res. · 2002 · 8 · 293
41. Liu Z. · Nat. Nanotechnol. · 2007 · 2 · 4710.1038/nnano.2006.170 ↗
42. Villa C. H. · Nano Lett. · 2008 · 8 · 422110.1021/nl801878d ↗
43. van Dijk M. · Bioconjugate Chem. · 2009 · 20 · 200110.1021/bc900087a ↗
44. Hong P. K. A. · J. Hazard. Mater. · 2002 · 94 · 25310.1016/S0304-3894(02)00067-5 ↗
45. Kang B. · Carbon · 2009 · 47 · 118910.1016/j.carbon.2008.12.031 ↗
46. Wang Y. · J. Pharm. Soc. Jpn. · 2008 · 128 · 94110.1248/yakushi.128.941 ↗
47. Lucente-Shultz R. M. · J. Am. Chem. Soc. · 2009 · 131 · 393410.1021/ja805721p ↗
48. Yokoi T. · Tumor Res. · 1988 · 23 · 43